Gilead's Biktarvy Profile Rises As CHMP Backs Daily HIV Therapy
Executive Summary
Biktarvy's strength in battle against ViiV Healthcare's dolutegravir franchises is seen as a 'double-edged sword' for Gilead in HIV contest amid foreseen old drug 'cannibalization'.